J&J MedTech Advances into Surgical Robotics with Ottava Clinical Trials

Johnson & Johnson’s MedTech division has secured an Investigational Device Exemption (IDE) for its Ottava robotic surgical system, allowing for clinical trials in the United States. This marks a significant step for J&J as it enters a surgical robotics market currently led by Intuitive Surgical’s Da Vinci systems. The trials aim to gather essential safety and effectiveness data, paving the way for market approval and potentially revolutionising surgical procedures.

For years, J&J MedTech has teased its entry into the robotic surgery space with Ottava, but faced delays due to the pandemic and technical challenges. With its IDE approval, Ottava stands out with four low-profile robotic arms that integrate directly into the operating table, conserving space and enhancing surgical flexibility. Its “twin motion” feature allows synchronised movement of the table and robotic arms, enabling easier access to different surgical quadrants. These innovative features could enhance surgical precision and efficiency, positioning Ottava as a strong competitor in the $8.6 billion surgical robotics market, which is expected to grow to $10 billion by year-end.

As J&J prepares for Ottava’s clinical trials, the company anticipates significant advancements in robotic surgical procedures. With instruments from Ethicon and the support of J&J’s Polyphonic digital platform, Ottava is poised to offer advanced insights and aid clinical decision-making. This development could not only bolster J&J’s standing in the medtech industry but also drive innovation in healthcare robotics, promising improved outcomes for surgeons and patients alike.